Phase 1 Study of LQT-1213 in Healthy Adults

Exclusion Criteria

• •Clinically significant diseases or any other condition, which, in the opinion of the Investigator, would jeopardize the safety of the participant or impact the validity of the study results.
• •Clinically significant abnormal findings on the physical examination or medical history during screening as deemed by the principal investigator
• •Female who is lactating
• •Female who is pregnant
• •Male participants with a history of oligospermia or azoospermia or any other disorder of the reproductive system
• •Male participants who are undergoing treatment or evaluation for infertility.
• •History of significant hypersensitivity to LQT-1213, kinase inhibitors or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
• •Use of immunosuppressant in the 28 days prior to the first study drug administration
• •Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (\> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
• •Intake of an investigational product or participation in a clinical trial in the 90 days prior to the first study drug administration